Please login to the form below

Not currently logged in
Email:
Password:

Sepracor signs EU marketing deal with GSK

Sepracor signs an agreement to market its sleep drug Lunivia with GSK in the EU

US-headquartered drug development company Sepracor has signed an agreement to market its sleep drug Lunivia (eszopiclone) in the EU with UK-based pharmaceutical company, GlaxoSmithKline (GSK).

Lunivia is currently under market review in the region, but has been commercially available in the US as Lunesta since 2005 to treat insomnia. Per the agreement, the drug will be marketed by GSK everywhere, except the US, Canada, Japan and Mexico.

Sepracor will receive an initial payment of USD 20m from GSK and is entitled to USD 155m in license and milestone payments, as well as double-digit royalties which would escalate upon increased product sales, says the firm.

In FY06, US product sales were about USD 566.8m, while the EU sedative hypnotic market was estimated to be worth about USD 500m in 2006.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics